LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). It can trigger an immune response in individuals expressing different HLA-A*02 subtypes (A*02:01, A*02:03, A*02:06, and A*02:07). This peptide induces a strong IFN-γ secretion response, stimulating the production of a high proportion of CD8+ IFN-γ+ T cells. It also induces specific CTLs to effectively kill target cells expressing LMP2A. It is used in the study of EBV-related malignant tumors such as Hodgkin's disease and nasopharyngeal carcinoma.
- Induces IFN-γ secreting cells at a frequency of 80.6 SFC/5x10⁴ CD8+ T cells (at 20 μg/mL for 24 h).
- Significantly increases the proportion of CD8+IFN-γ+ cells (at 20 μg/mL for 2 weeks).
- Specific CTLs effectively kill peptide-pulsed T2 cells and 293T-LMP2A cells (at 20 μg/mL for 4 h).